Paul has a wealth of experience in the international life sciences industry and investment banking, and will oversee VarmX’s finance department, whilst also bringing his leadership to the legal and IT functions.
Most recently, Paul served as CFO at Polyganics, a medical technology company that develops and commercializes bioresorbable devices for tissue repair and regeneration.Prior to Polyganics, he was CFO at IRX and Synthon, a privately-held specialty pharmaceutical company with gross revenue of over EUR 250 million and operations in six countries.
Paul began his career in the Corporate Finance division of Kempen & Co, a leading Dutch merchant bank. He advanced through a range of positions, ultimately becoming Executive Director of the Life Sciences/ Healthcare team. While at Kempen & Co, he advised on more than 35 M&A and capital market transactions, including successful exits and IPOs.
Paul holds Master’s degrees in Econometrics and Business Economics (both with honours) from the University of Amsterdam. In 2017, he completed the Emerging CFO program at Stanford University. Additionally, he was a non-executive director at Quirem Medical, a medical device company focused on selective internal radiotherapy, from 2015 until its acquisition by Terumo in 2020.